Novartis ADR Aktie News

The drugmaker reported third-quarter profit of $3.93 billion after higher sales for key drugs allowed it to offset a hit from patent expirations.

Swiss drugmaker Novartis , on a deal-making spree this year, reported a gain in operating income of 6% as growth of its new drugs made up for stagnant revenue from established heart drug Entresto.

Novartis AG (NYSE:NVS ) M&A Call October 27, 2025 8:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Robert Baloh Norman Putzki - Global Program Head of Neuroscience Conference Call Participants Sachin Jain - BofA Securities, Research Division Harry Sephton Seamus Fernandez - Gugge...

Novartis AG (ADR) (NYSE:NVS) announced it will acquire San Diego-based biopharmaceutical firm Avidity Biosciences (NASDAQ:RNA), which is developing RNA therapeutics for genetic neuromuscular diseases, in a transaction valued at approximately US$12 billion. The deal, unanimously approved by the boards of both companies, is designed to enhance Novartis' neuroscience pipeline with Avidity's late-s...

Stock futures are pointing to a sharply higher open this morning after major indexes closed last week at record highs; investor sentiment is getting a boost after President Donald Trump said he was optimistic the U.S. would reach a trade deal with China and address ownership of social media app TikTok; Avidity Biosciences (RNA) shares are surging after Swiss pharmaceutical maker Novartis (NVS) ...

President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week. Novartis announced it will buy Avidity Biosciences.

Avidity Biosciences (RNA) surges 42% premarket after Novartis agrees to acquire the company for $12 billion, paying $72 per share in cash. The RNA deal signals renewed Big Pharma interest in RNA therapies, with Dyne Therapeutics (DYN) up 21% on expectations of sector-wide benefits.

Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CEO Vas Narasimhan.